Source: Annual Congress 2005 - Resistant and MDR tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
V. A. Budnik, A. P. Astrauko, A. M. Skrahina, E. R. Sahalchyk (Minsk, Belarus). Risk factors of development of amplified Mtb resistance to antituberculous drugs. Eur Respir J 2005; 26: Suppl. 49, 4130

Member's Comments

No comment yet.

Related content which might interest you: Rational use of tuberculosis drugs to prevent the development of drug resistance Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017 Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009 Risk factors for anti-tuberculosis treatment failure Source: Annual Congress 2011 - Tuberculosis epidemiology and public health Year: 2011 Initial antituberculosis drugs resistance Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006 Outcome of multidrug resistant tuberculosis (MDR-TB) treatment with possible influencing factors Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Evaluation the drug susceptibility testing and the prevalence of resistance to antituberculosis drugs in a chronic department Source: Eur Respir J 2003; 22: Suppl. 45, 520s Year: 2003 Efficacy of anti-tuberculosis therapy with INH, RIF and Bedaquiline in mice with different genetic susceptibility to the infection Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019 Risk factors for rifampicine resistant tuberculosis cases and treatment results with standard regimens Source: Annual Congress 2008 - Outcomes of tuberculosis treatment Year: 2008 The main clinical problem of increasing resistance of Mycobacterium tuberculosis (MT) to first-line anti-TB drugs Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005 Second-line anti-tuberculosis drug concentrations for susceptibility testing in the MODS assay Source: Eur Respir J 2013; 41: 1163-1171 Year: 2013 Treatment results of multidrug resistant tuberculosis and the factors affecting treatment results Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008 Evaluation of therapeutic response in isoniazid resistant TB Source: Eur Respir J 2006; 28: Suppl. 50, 846s Year: 2006 Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Treatment of resistant tuberculosis in patients having isolates resistant to multiple antituberculosis drugs Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010 Risk factors of hepatotoxicity during tuberculosis treatment and management Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis I Year: 2008 Prevalance of initial and acquired resistance to antituberculosis drugs in our clinic Source: Eur Respir J 2005; 26: Suppl. 49, 653s Year: 2005 Resistance to second-line antituberculous drugs of Mtb strains in TB institute clinic Source: Eur Respir J 2007; 30: Suppl. 51, 442s Year: 2007